Cynosure (NSDQ:CYNO) shares are down 6% today after the medical aesthetics company reported a swing to 3rd-quarter red.
Cosmetic/Aesthetic
Aesthetic: Allergan lands FDA win for Juvederm facial filler
Syneron lands 510(k), CE Mark for VelaShape III
Syneron Medical Ltd. (NSDQ:ELOS) said it won a pair of regulatory nods for its VelaShape III "body shaping" device.
Solta Medical calls for help in seeking new CEO
California aesthetics devices maker Solta Medical (NSDQ:SLTM) engaged an executive recruiting firm to help fill the empty seat left behind by former CEO Stephen Fanning.
Syneron takes a hit on Q2 stumble
Syneron Medical Ltd. (NSDQ:ELOS) stumbled during the 2nd quarter, posting earnings that were even with Wall Street’s forecast but just missing sales expectations, sending share prices down this week.
Syneron lands Korean approval for skin-lightening product
Israel-based aesthetic device company Syneron Medical (NSDQ:ELOS) landed Korean regulatory approval for its elure skin-lightening product, a victory the company touts as crucial in a high-demand market.
Allergan’s Q2 sales, profits rise
Allergan (NYSE:AGN) shares ticked up today on strong 2nd-quarter sales and earnings numbers, including a 7.4% top-line gain for its medical device segment.
Irvine, Calif.-based Allergan reported profits of $359.9 million, or $1.17 per share, on sales of $1.60 billion for the 3 months ended June 30, for bottom-line growth of 21.8% on sales growth of 10.2%.
Cynosure closes $287 Palomar Medical buyout
Tria Beauty raises $40M in an open-ended funding round
Cosmetic medical device company Tria Beauty Inc. has so far raised $40 million in an open-ended equity funding round, and 13 unnamed investors are contributing to the pot, according to regulatory documents.
The Pleasanton, Calif.-based company expects to wrap up the offering by 2015 with no cap on the total raised, according to company filings. Tria went public 1 year ago in an IPO underwritten by Morgan Stanley and Wells Fargo.
Allergan poised for 2013 launch pending novel FDA OK for facial filler
Allergan rebounds after Q1 numbers send shares down 13%
Allergan (NYSE:AGN) took a ride on the wild side this week as Wall Street pounded the medical aesthetics company after its 1st-quarter earnings release, initially sending share down more than 13%.
Some of the selloff appeared related to news that Irvine, Calif.-based Allergan is delaying the rollout of Darpin, its macular degeneration drug. Investors were also spooked by lowered guidance for 2013 and a bottom-line writedown over the sale of its Lap-Band business.